Drug Type Antibody drug conjugate (ADC) |
Synonyms |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), SORT1 inhibitors(Sortilin inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC26H24FN3O6 |
InChIKeyPLXLYXLUCNZSAA-QLXKLKPCSA-N |
CAS Registry1599440-33-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 07 Nov 2023 |